Safety and effect of biphasic insulin aspart 50 [insulin aspart/insulin protamine aspart] compared to biphasic human insulin 50 [insulin suspension isophane/insulin] in patients with type 2 diabetes mellitus.

Trial Profile

Safety and effect of biphasic insulin aspart 50 [insulin aspart/insulin protamine aspart] compared to biphasic human insulin 50 [insulin suspension isophane/insulin] in patients with type 2 diabetes mellitus.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Dec 2014

At a glance

  • Drugs Insulin aspart/insulin protamine aspart (Primary) ; Insulin suspension isophane/insulin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 20 May 2009 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.
    • 20 May 2009 Planned number of patients changed from 75 to 81 as reported by ClinicalTrials.gov.
    • 07 Dec 2007 Status change from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top